Notice NOT-OD-20-024 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-023 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-018 from the NIH Guide for Grants and Contracts

Notice NOT-HL-19-730 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-017 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-21-002 from the NIH Guide for Grants and Contracts. This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors involved, the multiple cell types involved and the mechanisms underlying rejuvenation or accelerated aging that is observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation or accelerated aging will be obtained from research supported under this FOA.

Funding Opportunity RFA-AG-21-010 from the NIH Guide for Grants and Contracts. Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.

Funding Opportunity RFA-HD-21-013 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support innovative, multidisciplinary, interactive, and synergistic program projects that integrate basic, translational, and clinical approaches to understanding the developmental biology and genetic basis of significant congenital human malformations. To contain costs, each program project will consist of only three component research projects, as well as associated cores. At least one project must use basic research in an animal model system and at least one project must be clinical or translational in nature. The component research projects must share a common central theme, focus, or objective on a specific major developmental defect or malformation that is genotypically, mechanistically, biologically, or phenotypically analogous or homologous in both animal models and humans. Any non-mammalian or mammalian animal model may be used, as long as it contributes to the common overall theme or objective of the program project. The component research projects should share a common developmental gene, process, mechanism, pathway, or phenotype.

Notice NOT-AG-20-010 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-013 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-20-331 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research applications to elucidate mechanisms of neuroimmune dysfunction caused by HIV-1 and to detect persistent/latent/reactivated HIV using novel imaging/neuroimaging approaches in the central nervous system in anti-retroviral therapy (ART) suppressed individuals. ?These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. Basic, preclinical and clinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Funding Opportunity RFA-MH-20-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research applications to elucidate mechanisms of neuroimmune dysfunction caused by HIV-1 and to detect persistent/latent/reactivated HIV using novel imaging/neuroimaging approaches in the central nervous system from anti-retroviral therapy (ART) suppressed individuals. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R21 announcement, RFA MH-20-331 . Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Notice NOT-HL-19-731 from the NIH Guide for Grants and Contracts

Notice NOT-AI-20-017 from the NIH Guide for Grants and Contracts

Notice NOT-DK-20-003 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-017 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-019 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HS-20-001 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ) seeks applications to develop, implement, evaluate, and disseminate strategies to improve the management of opioid use and opioid use disorder (OUD) in older adults in primary care settings, especially in settings with large segments of socially at-risk older adults. Applicants must propose a comprehensive plan that uses evidence-based interventions and quality improvement strategies designed to improve the management of pain, opioid use, and opioid use disorder for older adults in primary care.

Notice NOT-HL-19-744 from the NIH Guide for Grants and Contracts